KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Free Cash Flow (2016 - 2025)

Merck (MRK) has disclosed Free Cash Flow for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 27.42% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $12.4 billion, a 31.7% decrease, with the full-year FY2025 number at $12.4 billion, down 31.7% from a year prior.
  • Free Cash Flow was $1.8 billion for Q4 2025 at Merck, down from $6.8 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $8.5 billion in Q3 2024 to a low of -$743.0 million in Q4 2023.
  • A 5-year average of $3.1 billion and a median of $3.0 billion in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 2290.51% in 2022, then crashed 122.65% in 2023.
  • Merck's Free Cash Flow stood at $3.9 billion in 2021, then dropped by 15.59% to $3.3 billion in 2022, then plummeted by 122.65% to -$743.0 million in 2023, then surged by 438.22% to $2.5 billion in 2024, then dropped by 27.42% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Free Cash Flow are $1.8 billion (Q4 2025), $6.8 billion (Q3 2025), and $2.5 billion (Q2 2025).